A randomized phase 3 trial of thalidomide and prednisone (TP) as maintenance therapy following autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM): An updated analysis of the NCIC Clinical Trials Group MY10 trial.
Annette E. Hay
Research Funding - Celgene
Suzanne Trudel
Honoraria - Celgene
Nizar J. Bahlis
Honoraria - Celgene
Research Funding - Celgene
Darrell White
Honoraria - Celgene
Waleed Sabry
No relevant relationships to disclose
Andrew Belch
Consultant or Advisory Role - Celgene
Tony J. Reiman
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Research Funding - Celgene
Jean Roy
No relevant relationships to disclose
Chaim Shustik
No relevant relationships to disclose
Michael J. Kovacs
No relevant relationships to disclose
Jonathan Sussman
No relevant relationships to disclose
Donna Ellen Reece
Consultant or Advisory Role - Celgene; Janssen; Johnson & Johnson; Onyx
Honoraria - Amgen; Celgene; Janssen; Otsuka
Research Funding - Bristol-Myers Squibb; Celgene; Janssen; Johnson & Johnson; Merck; Millennium; Novartis; Otsuka
Martha Lacy
Research Funding - Celgene
Ralph M. Meyer
Consultant or Advisory Role - Celgene
Lois E. Shepherd
No relevant relationships to disclose
Kate Whelan
No relevant relationships to disclose
Liting Zhu
No relevant relationships to disclose
Judy-Anne W. Chapman
No relevant relationships to disclose
A. Keith Stewart
Consultant or Advisory Role - Celgene